 | Up a level |
2018
Javle, M., Kelley, R. K., Roychowdhury, S., Weiss, K. H., Abou-Alfa, G. K., Macarulla, T., Sadeghi, S., Waldschmidt, D., Zhu, A. X., Goyal, L., Borad, M., Yong, W. P., Borbath, I., El-Khoueiry, A., Philip, P., Moran, S., Ye, Y., Ising, M., Lewis, N. and Bekaii-Saab, T. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann. Oncol., 29. S. 720 - 721. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2014
Giannelli, G., Faivre, S., Santoro, A., Kelley, R. K., Merle, P., Gane, E., Douillard, J. -Y., Waldschmidt, D., Mulcahy, M., Costentin, C., Minguez, B., Papappicco, P. P., Gueorguieva, I., Cleverly, A., Desaiah, D., Lahn, M. M., Ameryckx, S., Benhadji, K. A. and Raymond, E. (2014). EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-beta RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD. J. Hepatol., 60 (1). S. S52 - 2. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1600-0641